Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-01 · accession 0001209191-22-001284 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-04 | 2022-01-01 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +800.0K | 4.05M | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-01 | A | A | 800,000 | $0.00 | 4,045,828 | D | — | — | (F1) Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined goals related to the advancement of the Company's market capitalization that must be achieved within four years. If the goals are not met within the required time periods, the award will be forfeited in part or in whole. (F2) Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole. |